TransEnterix

Asensus Surgical, Inc. is a medical device company, which digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and addresses the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System features a machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit (ISU) that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world while staying true to the principles of value-based healthcare. The company was founded by William N. Starling on August 19, 1988 and is headquartered in Durham, NC.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TRXC stock has undergone a name change but that doesn't change the nature of the investment, for better or for worse. The post Transenterix Stock Has More Problems Than a Simple Name Change Can Fix appeared first on InvestorPlace.

Transenterix Stock Has More Problems Than a Simple Name Change Can Fix

Asensus Surgical

Whether you're looking to invest in TRXC stock or its successor, Asensus Surgical, you'll need something to handle the volatility.   The post TransEnterix or Asensus Surgical?

TransEnterix or Asensus Surgical? Let's Call the Whole Thing Off

TransEnterix (TRXC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

TransEnterix (TRXC) Moves to Buy: Rationale Behind the Upgrade

Asensus and TRXC stock has gotten a $1 billion market cap on introducing Senhance, a robotic surgery system for abdominal surgery. Knowing whether it will succeed will take time.

Only Patience Will Be Rewarded With Asensus

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: TRXC) (formerly TransEnterix, Inc.), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release fourth quarter and fiscal year 2020 financial and operating results after the market closes on Thursday, March 11, 2021. The Company will host a conference call to discuss these results starti

Asensus Surgical, Inc. Schedules Fourth Quarter and Fiscal Year 2020 Financial and Operating Results Conference Call for March 11, 2021

Shares of TRXC stock are rising on Wednesday after the firm received general surgery clearance from the FDA for its Senhance Surgical System. The post TRXC Stock: Why Medical Device Play Asensus Surgical Is Soaring Today appeared first on InvestorPlace.

TRXC Stock: Why Medical Device Play Asensus Surgical Is Soaring Today

The stock price of Asensus Surgical Inc (NYSEAMERICAN: TRXC) has increased by over 35% pre-market. This is why it happened.

TRXC Stock Price Increases Over 35% Pre-Market: Why It Happened

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (formerly TransEnterix, Inc.) (NYSE American: TRXC) , a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, today announced the Company has received an additional FDA clearance for the Senhance Surgical System which allows for indication expansion in general surgery in the United States. Asensus Surgical's technology platform, Senhance® S

Asensus Surgical Announces FDA Clearance in General Surgery

TRXC stock is a better option than many “meme” stocks that retail investors have bid higher. It's a reminder that a little bit of homework can go a long way.

TransEnterix Has a Lesson That Reddit Investors Should Take Time to Learn

TransEnterix (TRXC) closed at $3.72 in the latest trading session, marking no change from the prior day.

TransEnterix (TRXC) Flat As Market Gains: What You Should Know

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: TRXC) (formerly TransEnterix, Inc.), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery, announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H.C. Wainwright Virtual Global Life Sciences Conference

Asensus Surgical to Present at the H.C. Wainwright Virtual Global Life Sciences Conference

Shares of the robotic surgical-system manufacturer are soaring, but can this company become the next Intuitive Surgical?

Is TransEnterix a Good Stock to Buy Now?

TRXC stock has pulled off a nice rally. But the company's systems could take some time to get traction.

Even After the Name Change, TransEnterix Lacks the Momentum It Needs

TRXC stock could become the next Intuitive Surgical. The company is funded, and has to simply develop its business now.

TransEnterix Has Strong Funding and a Burgeoning Market

TransEnterix announced a company renaming amid a broad selloff that had TRXC stock down more than 15% in trading today. The post TRXC Stock: What to Know as Red-Hot TransEnterix Falls 17% Today appeared first on InvestorPlace.

TRXC Stock: What to Know as Red-Hot TransEnterix Falls 17% Today

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it will change its corporate name to Asensus Surgical, Inc. The name change reflects the company's broader vision of shaping the future of surgery by integrating computer vision and machine learning with surgical robotics. While the company name change is e

TransEnterix Announces Name Change to Asensus Surgical and Introduces a New Category of Surgery, Performance-Guided Surgery

TRXC stock has struggled badly since its 2014 IPO. A trader-driven rally is unlikely to change the concerning long-term trend.

A ‘Reddit Rally' Doesn't Make TransEnterix a Long-Term Buy

As TRXC stock takes a breather amid a sustained uptrend, investors should consider owning shares of this medical robotics innovator. The post Make a Surgical Strike With TransEnterix Stock appeared first on InvestorPlace.

Make a Surgical Strike With TransEnterix Stock

With its ultra-low price point and the relevant business of minimally invasive surgeries, TRXC stock has garnered much attention. Still, prospective buyers should look at the broader context before diving in.

Here's a Second Opinion For Those Considering Entering Transenterix Stock

Is (TRXC) Outperforming Other Medical Stocks This Year?

Is TransEnterix (TRXC) Outperforming Other Medical Stocks This Year?

Intuitive Surgical

TRXC stock has potential to become the next Intuitive Surgical with its Senhance platform opening up a multi-billion dollar revenue stream The post TransEnterix Has A Compelling Case To Be The Next Intuitive Surgical appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next Potential Winner It doesn't matter if you have $500 in savings or $5 million.

TransEnterix Has A Compelling Case To Be The Next Intuitive Surgical

Does TransEnterix (TRXC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Momentum Investors Will Love TransEnterix (TRXC)

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced the Company has agreed to partner with the Amsterdam Skills Centre (ASC) in the Netherlands for surgical training. This site will serve surgeons and staff throughout Europe with basic and advanced training on the Senhance® Surgical System. The ASC will also prov

TransEnterix Announces New Training Center in EU

TransEnterix is facing competition from a number of much larger companies, while its revenue is quite low. Investors should take profits on TRXC stock.

TransEnterix Doesn't Have What It Takes to Be a Long-Term Investment

So, after contrasting the opportunities and risks with TRXC stock, what's the play? It may be interesting at lower prices.

News for TransEnterix Stock (TRXC)